在整个功能谱的高级心间阻塞
Marco Marano1, Luigi Senigalliesi1, Rossella Cocola1
1Unit of Nephrology and Dialysis, Maria Rosaria Clinic, Via Colle San Bartolomeo, 80045 Pompei, Italy.
Medicina (Kaunas, Lithuania)
|June 27, 2024
概括
随着功能恶化,先进心脏间阻塞 (IAB) 的患病率会增加,特别是在慢性病 (CKD) 和末期病 (ESKD) 患者中. 这种情况可能表明尿路性心肌病,需要进一步的预后调查.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 电子生理学 电子生理学
背景情况:
- 心房间隔阻塞 (IAB) 表示右心房和左心房之间的导电延迟.
- 有限的数据存在于慢性病 (CKD) 阶段的部分和高级IAB患病率.
- 了解CKD中的IAB对于评估病中的心脏影响至关重要.
研究的目的:
- 确定患有不同程度功能,包括透析患者的晚期IAB的患病率和模式.
- 在慢性病的背景下,确定与晚期IAB相关的临床特征.
主要方法:
- 一项回顾性,单中心研究包括151名患者,按CKD阶段分类.
- 评估了IAB的流行,模式和相关的临床因素.
- 将患有CKD和末期病 (ESKD) 的患者与对照组进行了比较.
主要成果:
- 在CKD (17.8%) 和ESKD (24.5%) 组中,与对照组 (5.3%) 相比,先进的IAB患病率显著更高.
- 在ESKD (36.7%) 和对照组 (59.6%) 中,部分IAB的患病率较低.
- 非典型的IAB模式在CKD和ESKD患者中更频繁.
结论:
- 渐进性功能下降与IAB发病率的增加相关.
- 先进的IAB可以作为尿路性心肌病的指标.
- 需要进一步的研究来确定晚期IAB在CKD的预后意义.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Factors Affecting Renal Clearance: Renal Impairment
81
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
81
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735


